GSK Pharma Shares Soar 20% on Stellar Q3 Results

GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) shares hit the 20% upper circuit on Monday, February 17, 2025, following its impressive Q3 FY25 results. The company reported a 402% year-on-year increase in consolidated net profit to ₹228.58 crore, driven by strong performance across key product portfolios. Revenue from operations rose 17.5% to ₹946.36 crore. GSK's flagship brands, including Augmentin and Ceftum, gained market share, while its innovative respiratory portfolio led by Nucala and Trelegy achieved robust growth. The company maintained its leadership in the self-pay private market for pediatric vaccines and is expanding its adult immunization segment with Shingrix.

 

Sources: Business Standard, Financial Express, CNBC TV18